Drug Channels Archive for February, 2023


Click a link below to view the mailing archive as if it had been sent to you.

2023-02-28 07:47Drug Channels News Roundup, February 2022: Mark Cuban vs. PBMs, MDs on Humira Biosimilars, States vs. PBMs, 340B Transparency, and Health Insurer Humor (?)
2023-02-24 07:47Drug Channels - Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success
2023-02-22 07:47Drug Channels - Copay Accumulator and Maximizer Update: Adoption Plateaus as Insurers Battle Patients Over Copay Support
2023-02-21 07:47Drug Channels - Available for Preorder: The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
2023-02-17 07:47Drug Channels - Improve Access, Affordability, and Brand Performance With GoodRx's Point-of-Sale Rebate Programs
2023-02-14 07:47Drug Channels - Exclusive: Profiling Manufacturers' Limited and Exclusive Pharmacy Networks for Specialty Drugs
2023-02-10 07:47Drug Channels - The Top Indicators That a Hub Launch Will Succeed: Discovery and Partnership
2023-02-07 07:47Drug Channels - The Warped Incentives Behind Amgen's Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha
2023-02-06 07:47Drug Channels - Informa Connect's Access USA

 

<< Archive IndexSubscribe >>